Cited by 379Bone health and osteoporosis researchBone health and treatmentsBone Metabolism and Diseases

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

Open access

Boonen, Steven, Reginster, Jean-Yves, Kaufman, Jean-Marc, Lippuner, Kurt, Zanchetta, Jose, Langdahl, Bente, Rizzoli, Rene, Lipschitz, Stanley, Dimai, Hans Peter, Witvrouw, Richard, Eriksen, Erik, Brixen, Kim, Russo, Luis, Claessens, Frank, Papanastasiou, Philemon, Antunez, Oscar, Su, Guoqin, Bucci-Rechtweg, Christina, Hruska, Josef, Incera, Elodie, Vanderschueren, Dirk, Orwoll, Eric·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1204061

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis. METHODS: In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1199 men with primary or hypogonadism-associated osteoporosis who were 50 to 85 years of age to receive an intravenous infusion of zoledronic acid (5 mg) or placebo at baseline and at 12 months. Participants received daily calcium and vitamin D supplementation. The primary end point was the proportion of participants with one or more new morphometric vertebral fractures over a period of 24 months. RESULTS: The rate of any new morphometric vertebral fracture was 1.6% in the zoledronic acid group and 4.9% in the placebo group over the 24-month period, representing a 67% risk reduction with zoledronic acid (relative risk, 0.33; 95% confidence interval, 0.16 to 0.70; P=0.002). As compared with men who received placebo, men who received zoledronic acid had fewer moderate-to-severe vertebral fractures (P=0.03) and less height loss (P=0.002). Fewer participants who received zoledronic acid had clinical vertebral or nonvertebral fractures, although this difference did not reach significance because of the small number of fractures. Bone mineral density was higher and bone-turnover markers were lower in the men who received zoledronic acid (P<0.05 for both comparisons). Results were similar in men with low serum levels of total testosterone. The zoledronic acid and placebo groups did not differ significantly with respect to the incidence of death (2.6% and 2.9%, respectively) or serious adverse events (25.3% and 25.2%). CONCLUSIONS: Zoledronic acid treatment was associated with a significantly reduced risk of vertebral fracture among men with osteoporosis. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00439647.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1204061

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,822
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
Johnell, O., & Kanis, J. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0172-4 · Cited by 4,770
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citation
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citation
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003
Self-citation
Mortality after all major types of osteoporotic fracture in men and women: an observational study
Nguyen, T. V., Schneider, D. L., Sambrook, P. N., & Eisman, J. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09075-8 · Cited by 1,926
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580

Flagged first, then by citations

Show all 30 references

Sorted by citations

Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
Khan, A. A., Morrison, A. D., Hanley, D. A., Felsenberg, D., McCauley, L. K., O’Ryan, F., Reid, I. R., Ruggiero, S. L., Taguchi, A., Tetradis, S., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2405 · Cited by 1,360
UK clinical guideline for the prevention and treatment of osteoporosis
The National Osteoporosis Guideline Group (NOGG), Compston, J. E., Cooper, A., Cooper, C. C., Gittoes, N. J. L., Gregson, C. L., Harvey, N. C., Hope, S., Kanis, J. А., McCloskey, E. V., et al. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0324-5 · Cited by 865
Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of physicians
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Adler, R. A., Fuleihan, G. E., Bauer, D. C., Camacho, P. M., Clarke, B. L., Clines, G. A., Compston, J. E., Drake, M. T., Edwards, B. J.-A., Favus, M. J., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2708 · Cited by 689
Screening for Osteoporosis to Prevent Fractures
US Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., et al. (2018) · JAMA · doi:10.1001/jama.2018.7498 · Cited by 668
UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., Harvey, N., Kanis, J., Leyland, S., Low, R., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01061-5 · Cited by 593
The rise of multiple imputation: a review of the reporting and implementation of the method in medical research
Rezvan, P. H., Lee, K. J., & Simpson, J. A. (2015) · BMC Medical Research Methodology · doi:10.1186/s12874-015-0022-1 · Cited by 483
Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Bouxsein, M., Eastell, R., Lui, L., Wu, L., de Papp, A. E., Grauer, A., Marín, F., Cauley, J. A., Bauer, D. C., Black, D. M., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3641 · Cited by 357
A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis
Lewiecki, E. M., Blicharski, T., Goemaere, S., Lippuner, K., Meisner, P. D., Miller, P. D., Miyauchi, A., Maddox, J., Chen, L., & Horlait, S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02163 · Cited by 332
Sex Steroid Actions in Male Bone
Vanderschueren, D., Laurent, M. R., Claessens, F., Gielen, E., Lagerquist, M. K., Vandenput, L., Börjesson, A. E., & Ohlsson, C. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1024 · Cited by 327
Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians
Ayers, C. K., Kansagara, D. L., Lazur, B. H., Fu, R. F., Kwon, A., & Harrod, C. S. (2023) · Annals of Internal Medicine · doi:10.7326/m22-0684 · Cited by 297
Long-term and sequential treatment for osteoporosis
Foessl, I., Dimai, H. P., & Obermayer-Pietsch, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00866-9 · Cited by 273
Guidelines for the diagnosis, prevention and management of osteoporosis
Rossini, M., Adámi, S., Bertoldo, F., Diacinti, D., Gatti, D., Giannini, S., Giusti, A., Malavolta, N., Minisola, S., Osella, G., et al. (2016) · Reumatismo · doi:10.4081/reumatismo.2016.870 · Cited by 279
Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures
Crandall, C. J., Newberry, S. J., Diamant, A. L., Lim, Y.-W., Gellad, W. F., Booth, M. J., Motala, A., & Shekelle, P. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0317 · Cited by 257
A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management
Grossmann, M., & Matsumoto, A. M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3580 · Cited by 246
Osteoporosis in Men: A Review of an Underestimated Bone Condition
Rinonapoli, G., Ruggiero, C., Meccariello, L., Bisaccia, M., Ceccarini, P., & Caraffa, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042105 · Cited by 254
National incidence of traumatic fractures in China: a retrospective survey of 512 187 individuals
Chen, W., Lv, H., Liu, S., Liu, B., Zhu, Y., Chen, X., Yang, G., Liu, L., Zhang, T., Wang, H., et al. (2017) · The Lancet Global Health · doi:10.1016/s2214-109x(17)30222-x · Cited by 243
Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians
Qaseem, A., Hicks, L. A., Etxeandia‐Ikobaltzeta, I., Shamliyan, T., & Cooney, T. G. (2023) · Annals of Internal Medicine · doi:10.7326/m22-1034 · Cited by 253
Osteoporosis in men
Vilaca, T., Eastell, R., & Schini, M. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00012-2 · Cited by 230
Overview of treatment approaches to osteoporosis
Langdahl, B. L. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15024 · Cited by 222
Screening to Prevent Osteoporotic Fractures
Viswanathan, M., Reddy, S., Berkman, N. D., Cullen, K., Middleton, J. C., Nicholson, W. K., & Kahwati, L. C. (2018) · JAMA · doi:10.1001/jama.2018.6537 · Cited by 223
The clinical epidemiology of male osteoporosis: a review of the recent literature
Nelson, R. E., Willson, T. M., Nelson, S. D., Newbold, J., & LaFleur, J. (2015) · Clinical Epidemiology · doi:10.2147/clep.s40966 · Cited by 191
Bisphosphonates for the prevention and treatment of osteoporosis
Maraka, S., & Kennel, K. A. (2015) · BMJ · doi:10.1136/bmj.h3783 · Cited by 181
Screening for Osteoporosis to Prevent Fractures
US Preventive Services Task Force, Nicholson, W. K., Silverstein, M., Wong, J. B., Chelmow, D. P., Coker, T. R., Davis, E. M., Jaén, C. R., Krousel-Wood, M. A., Lee, S., et al. (2025) · JAMA · doi:10.1001/jama.2024.27154 · Cited by 163
Muscle and Bone Mass Loss in the Elderly Population: Advances in diagnosis and treatment
Colón, C. J. P., Molina-Vicenty, I. L., Frontera-Rodríguez, M., García-Ferré, A., Rivera, B. P., Cintrón-Vélez, G., & Frontera-Rodríguez, S. (2018) · Journal of Biomedicine · doi:10.7150/jbm.23390 · Cited by 166
Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health
Golds, G., Houdek, D., & Arnason, T. (2017) · International Journal of Endocrinology · doi:10.1155/2017/4602129 · Cited by 150
Safety issues with bisphosphonate therapy for osteoporosis
Suresh, E., Pazianas, M., & Abrahamsen, B. (2013) · Rheumatology · doi:10.1093/rheumatology/ket236 · Cited by 141
Evidence-Based Guideline for the management of osteoporosis in men
Fuggle, N. R., Beaudart, C., Bruyère, O., Abrahamsen, B., Al‐Daghri, N. M., Burlet, N., Chandran, M., Rosa, M. M., Cortet, B., Demonceau, C., et al. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01094-9 · Cited by 145
Diagnosis and Management of Osteoporosis.
Jeremiah, M. P., Unwin, B., Greenawald, M. H., & Casiano, V. E. (2015) · PubMed · Cited by 130
Osteoporosis in men
Ebeling, P. R. (2013) · The biomedical & life sciences collection. · doi:10.1097/bor.0b013e328362164d · Cited by 131
Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis
Belaya, Z. E., Belova, K. Y., Biryukova, E. V., Dedov, I. I., Dzeranova, L. K., Drapkina, O. M., Dreval', A. V., Dubovitskaya, Т. A., Dudinskaya, Е. N., Ershova, O. B., et al. (2021) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12930 · Cited by 138
Renal safety in patients treated with bisphosphonates for osteoporosis: A review
Miller, P. D., Jamal, S. A., Evenepoel, P., Eastell, R., & Boonen, S. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2058 · Cited by 114
The 2024 UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D., Avgerinou, C., Bowden, J., Cooper, C. C., Douglas, L., Edwards, J., Gittoes, N. J. L., Harvey, N. C., Kanis, J. A., et al. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01588-3 · Cited by 136
Treatment of osteoporosis in men
Kaufman, J., Reginster, J.-Y., Boonen, S., Brandi, M. L., Cooper, C. C., Dere, W. H., Devogelaer, J.-P., Díez‐Pérez, A., Kanis, J. А., McCloskey, E. V., et al. (2012) · Bone · doi:10.1016/j.bone.2012.11.018 · Cited by 109
Osteoporosis in men: a review
Adler, R. A. (2014) · Bone Research · doi:10.1038/boneres.2014.1 · Cited by 109
Tea and bone health: steps forward in translational nutrition
Shen, C., Chyu, M., & Wang, J.-S. (2013) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.058255 · Cited by 100
The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis
Byun, J.-H., Jang, S., Lee, S., Park, S., Yoon, H. K., Yoon, B., & Ha, Y. (2017) · Journal of Bone Metabolism · doi:10.11005/jbm.2017.24.1.37 · Cited by 98
Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates
Cummings, S. R., Lui, L., Eastell, R., & Allen, I. E. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2779 · Cited by 99
Zoledronic Acid (Reclast®, Aclasta®): A Review in Osteoporosis
Dhillon, S. (2016) · Drugs · doi:10.1007/s40265-016-0662-4 · Cited by 96
Management of osteoporosis of the oldest old
Rizzoli, R., Branco, J., Brandi, M. L., Boonen, S., Bruyère, O., Cacoub, P., Cooper, C. C., Díez‐Pérez, A., Duder, J., Fielding, R. A., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2755-9 · Cited by 94
EAA clinical guideline on management of bone health in the andrological outpatient clinic
Rochira, V., Antonio, L., & Vanderschueren, D. (2018) · Andrology · doi:10.1111/andr.12470 · Cited by 90
Androgens and prostate cancer; pathogenesis and deprivation therapy
Grossmann, M., Cheung, A. S., & Zajac, J. D. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.001 · Cited by 91
Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses
Zhou, J., Ma, X., Wang, T., & Zhai, S. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3654-z · Cited by 84
Naringin prevents ovariectomy-induced osteoporosis and promotes osteoclasts apoptosis through the mitochondria-mediated apoptosis pathway
Li, F., Sun, X., Ma, J., Ma, X., Zhao, B., Zhang, Y., Tian, P., Li, Y., & Han, Z. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.117 · Cited by 82
Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta‐Analysis
Nayak, S., & Greenspan, S. L. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14668 · Cited by 80
Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis
Sanderson, J., James, M. M., Stevens, J., Goka, E., Wong, R., Campbell, F., Selby, P. L., Gittoes, N. J. L., & Davis, S. (2016) · Bone · doi:10.1016/j.bone.2016.05.013 · Cited by 77
Osteoporosis treatment: current drugs and future developments
Chen, Y., Jia, L.-H., Han, T.-H., Zhao, Z., Yang, J. M., Xiao, J., Yang, H., & Yang, K. Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1456796 · Cited by 82
Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)
Nakamura, T., Fukunaga, M., Nakano, T., Kishimoto, H., Ito, M., Hagino, H., Sone, T., Taguchi, A., Tanaka, S., Ohashi, M., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3736-y · Cited by 78
A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures
Davis, S., James, M. M., Sanderson, J., Stevens, J., Goka, E., Rawdin, A., Sadler, S., Wong, R., Campbell, F., Stevenson, M., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20780 · Cited by 76
The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation
Cianferotti, L., Bertoldo, F., Carini, M., Kanis, J. А., Lapini, A., Longo, N., Martorana, G. E., Mirone, V. G., Reginster, J., Rizzoli, R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17980 · Cited by 73
Osteoporosis Diagnosis in Men: The T-Score Controversy Revisited
Binkley, N., Adler, R. A., & Bilezikian, J. P. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0242-z · Cited by 73
Update on osteoporosis in men
Adler, R. A. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.05.007 · Cited by 77
Male osteoporosis
Bandeira, L., Silva, B. C. C., & Bilezikian, J. P. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000563 · Cited by 86
Management of Osteoporosis in Men: A Narrative Review
Vescini, F., Chiodini, I., Falchetti, A., Palermo, A., Salcuni, A. S., Bonadonna, S., Geronimo, V. D., Cesareo, R., Giovanelli, L., Brigo, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413640 · Cited by 71
Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. Sociedad Española de Investigación Ósea y del Metabolismo Mineral (3.ª versión actualizada 2014)
González-Macı́as, J., del Pino‐Montes, J., Olmos, J. M., & Nogués, X. (2015) · Revista Clínica Española · doi:10.1016/j.rce.2015.08.003 · Cited by 67
Effects of bisphosphonates on osteoporosis: Focus on zoledronate
Oryan, A., & Sahvieh, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118681 · Cited by 58
Osteoporosis in men
Walsh, J., & Eastell, R. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.171 · Cited by 57
Vitamin D, respiratory infections, and chronic disease: Review of meta‐analyses and randomized clinical trials
Ganmaa, D., Enkhmaa, D., Erdenebileg, N., Sukhbaatar, S., Tumur‐Ochir, K., & Manson, J. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13399 · Cited by 57
Repeating Measurement of Bone Mineral Density when Monitoring with Dual-energy X-ray Absorptiometry: 2019 ISCD Official Position
Kendler, D. L., Compston, J. E., CAREY, J. J., Wu, C., Ibrahim, A., & Lewiecki, E. M. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.07.010 · Cited by 53
Osteoporosis in older men: Recent advances in pathophysiology and treatment
Laurent, M. R., Gielen, E., Claessens, F., Boonen, S., & Vanderschueren, D. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.04.010 · Cited by 51
MANAGEMENT OF ENDOCRINE DISEASE: Male osteoporosis: diagnosis and management - should the treatment and the target be the same as for female osteoporosis?
Porcelli, T., Maffezzoni, F., Pezzaioli, L. C., Delbarba, A., Cappelli, C., & Ferlin, A. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0034 · Cited by 51
Biochemical Markers of Bone Turnover in Osteoporosis
Szulc, P., Bauer, D. C., & Eastell, R. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch35 · Cited by 51
Bibliometric analysis of global research trends on male osteoporosis: a neglected field deserves more attention
Wu, H., Sun, Z., Tong, L., Wang, Y., Yan, H., & Sun, Z. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-01016-2 · Cited by 50
Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis
Beaudart, C., Demonceau, C., Sabico, S., Veronese, N., Cooper, C. C., Harvey, N. C., Fuggle, N. R., Bruyère, O., Rizzoli, R., & Reginster, J. (2023) · Aging Clinical and Experimental Research · doi:10.1007/s40520-023-02478-9 · Cited by 51
Quality of Osteoporosis Care of Older Medicare Recipients with Fragility Fractures: 2006 to 2010
Liu, S. K., Munson, J. C., Bell, J., Zaha, R. L., Mecchella, J. N., Tosteson, A. N. A., & Morden, N. E. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12507 · Cited by 50
Treatment of primary osteoporosis in men
Bianchi, G., & Giusti, A. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s44057 · Cited by 54
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial
Czerwinski, E. J., Cardona, J., Plebanski, R., Recknor, C. P., Vokes, T., Saag, K. G., Binkley, N., Lewiecki, E. M., Adachi, J. D., Knychas, D., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4719 · Cited by 49
Zoledronic Acid in Osteoporosis Secondary to Mastocytosis
Rossini, M., Zanotti, R., Viapiana, O., Tripi, G., Idolazzi, L., Biondan, M., Orsolini, G., Bonadonna, P., Adami, S., & Gatti, D. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.06.015 · Cited by 48
Recovery From SIADH-Associated Osteoporosis: A Case Report
Sejling, A., Thorsteinsson, A., Pedersen‐Bjergaard, U., & Eiken, P. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1572 · Cited by 47
Comparison of three-dimensional printing and vacuum freeze-dried techniques for fabricating composite scaffolds
Sun, K., Li, R., Jiang, W., Sun, Y., & Li, H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.07.050 · Cited by 47
Screening for Osteoporosis to Prevent Fractures
Kahwati, L. C., Kistler, C. E., Booth, G., Sathe, N. A., Gordon, R. D., Okah, E. D., Wines, R., & Viswanathan, M. (2025) · JAMA · doi:10.1001/jama.2024.21653 · Cited by 47
Testosterone treatment in older men: clinical implications and unresolved questions from the Testosterone Trials
Yeap, B. B., Page, S. T., & Grossmann, M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30416-3 · Cited by 43
Mind the gap: Incidence of osteoporosis treatment after an osteoporotic fracture – results of the Austrian branch of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)
Malle, O., Borgström, F., Fahrleitner‐Pammer, A., Svedbom, A., Dimai, S. V., & Dimai, H. P. (2019) · Bone · doi:10.1016/j.bone.2019.115071 · Cited by 43
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis
Vescini, F., Attanasio, R., Balestrieri, A., Bandeira, F. A. F., Bonadonna, S., Camozzi, V., Cassibba, S., Cesareo, R., Chiodini, I., Francucci, C. M., et al. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0434-8 · Cited by 43
Bone Microarchitecture in Transgender Adults: A Cross-Sectional Study
Bretherton, I., Ghasem-Zadeh, A., Leemaqz, S., Seeman, E., Wang, X., McFarlane, T., Spanos, C., Grossmann, M., Zajac, J. D., & Cheung, A. S. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4497 · Cited by 41
Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools
Gates, M., Pillay, J., Nuspl, M., Wingert, A., Vandermeer, B., & Hartling, L. (2023) · Systematic Reviews · doi:10.1186/s13643-023-02181-w · Cited by 46
Bone outcomes following sleeve gastrectomy in adolescents and young adults with obesity versus non-surgical controls
Misra, M., Singhal, V., Carmine, B. J., Bose, A., Kelsey, M. M., Stanford, F. C., Bram, J., Aidlen, J. T., Inge, T. H., Bouxsein, M., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115290 · Cited by 42
The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong.
Ip, T., Cheung, S.-K. W., Cheung, S.-K. W., Cheung, T.-C., Choi, T.-C., Chow, S.-L. E., Kan, S.-Y. A., Kung, W. C. A., Lee, K.-K., Leung, K. L. F., et al. (2013) · PubMed · Cited by 41
The efficacy of 3D printing-assisted surgery for traumatic fracture: a meta-analysis
Xiong, L., Li, X., Li, H., Chen, Z., & Xiao, T. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136482 · Cited by 41
The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial
Black, D. M., Reid, I. R., Napoli, N., Ewing, S. K., Shiraki, M., Nakamura, T., Takeuchi, Y., Schafer, A. L., Kim, T. Y., & Cauley, J. A. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4434 · Cited by 39
Androgens Inhibit the Osteogenic Response to Mechanical Loading in Adult Male Mice
Sinnesael, M., Laurent, M. R., Jardí, F., Dubois, V., Deboel, L., Delisser, P., Behets, G. J. S., D’Haese, P. C., Carmeliet, G., Claessens, F., et al. (2015) · Endocrinology · doi:10.1210/en.2014-1673 · Cited by 38
Causes, consequences, and treatment of osteoporosis in men
Banu, J. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s46101 · Cited by 40
Promoting mobility and healthy aging in men: a narrative review
Ebeling, P. R., Cicuttini, F., Scott, D. S., & Jones, G. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05080-w · Cited by 38
Benefits of Bisphosphonate Therapy: Beyond the Skeleton
Billington, E. O., & Reid, I. R. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00612-4 · Cited by 38
Male Osteoporosis in the Elderly
D’Amelio, P., & Isaia, G. C. (2015) · International Journal of Endocrinology · doi:10.1155/2015/907689 · Cited by 37
Practical guidance for the use of bisphosphonates in osteoporosis
Compston, J. E. (2020) · Bone · doi:10.1016/j.bone.2020.115330 · Cited by 42
Bone health in ageing men
David, K., Narinx, N., Antonio, L., Evenepoel, P., Claessens, F., Decallonne, B., & Vanderschueren, D. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09738-5 · Cited by 37
Osteoporosis in Men: Epidemiology, Pathophysiology, and Clinical Characterization
ORWOLL, E. S., & KLEIN, R. F. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50044-6 · Cited by 35
Effect of Cornus Officinalis on Receptor Activator of Nuclear Factor-kappaB Ligand (RANKL)-induced Osteoclast Differentiation
Kim, J. Y., Kim, Y.-K., Choi, M. K., Oh, J., Kwak, H. B., & Kim, J.-J. (2012) · Journal of Bone Metabolism · doi:10.11005/jbm.2012.19.2.121 · Cited by 35
Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective
Silverman, S. L., Agodoa, I., Kruse, M., Parthan, A., & ORWOLL, E. S. (2015) · Journal of Osteoporosis · doi:10.1155/2015/627631 · Cited by 34
Machine Learning Approaches for Fracture Risk Assessment: A Comparative Analysis of Genomic and Phenotypic Data in 5130 Older Men
Wu, Q. F., Nasoz, F., Jung, J.-Y., Bhattarai, B. D., & Han, M. (2020) · Calcified Tissue International · doi:10.1007/s00223-020-00734-y · Cited by 34
Low-molecular weight fucoidan inhibits the differentiation of osteoclasts and reduces osteoporosis in ovariectomized rats
Jin, X., Zhu, L., Li, X., Jia, J., Zhang, Y., Sun, X., Ma, J., Liu, Z., & Ma, X. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.6062 · Cited by 34
Odanacatib, a Selective Cathepsin K Inhibitor, Demonstrates Comparable Pharmacodynamics and Pharmacokinetics in Older Men and Postmenopausal Women
Anderson, M. S., Gendrano, I. N., Liu, C., Jeffers, S., Mahon, C., Mehta, A., Mostoller, K., Zajic, S. C., Morris, D., Lee, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1688 · Cited by 33
Comparison of fracture risk assessment tools in older men without prior hip or spine fracture: the MrOS study
Gourlay, M. L., Ritter, V., Fine, J. P., Overman, R. A., Schousboe, J. T., Cawthon, P. M., ORWOLL, E. S., Nguyen, T. V., Lane, N. E., Cummings, S. R., et al. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0389-1 · Cited by 33
Idiopathic Osteoporosis in Men
Gennari, L., & Bilezikian, J. P. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-013-0164-1 · Cited by 32
New and developing pharmacotherapy for osteoporosis in men
Gennari, L., & Bilezikian, J. P. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1428559 · Cited by 34
Intravenous Treatment With Ibandronate Normalizes Bone Matrix Mineralization and Reduces Cortical Porosity After Two Years in Male Osteoporosis: A Paired Biopsy Study
Misof, B. M., Patsch, J., Roschger, P., Muschitz, C., Gamsjaeger, S., Paschalis, E. P., Prokop, E., Klaus Klaushofer, A., Pietschmann, P., & Resch, H. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2035 · Cited by 31
Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women
Bai, H., Jing, D., Guo, A., & Yin, S. (2013) · Journal of International Medical Research · doi:10.1177/0300060513480917 · Cited by 31
Celiac Disease and Its Role in the Development of Metabolic Bone Disease
Micić, D., Rao, V. L., & Semrad, C. E. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.06.005 · Cited by 34
Management of comorbidities in haemophilia
Kempton, C. L., Makris, M., & Holme, P. A. (2020) · Haemophilia · doi:10.1111/hae.14013 · Cited by 31

Authors: Boonen, S., Reginster, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., Eriksen, E., Brixen, K., Russo, L., Claessens, F., Papanastasiou, P., Antunez, O., Su, G., Bucci-Rechtweg, C., Hruska, J., Incera, E., Vanderschueren, D., & Orwoll, E.
Affiliations: KU Leuven (BE)
University of Liège (BE)
Ghent University (BE)
University of Bern (CH)
Aarhus University Hospital (DK)
Medical University of Graz (AT)
Ziekenhuis Oost-Limburg (BE)
University of Oslo (NO)
University of Southern Denmark (DK)
Novartis (Switzerland) (CH)
Oregon Health & Science University (US)
ORCID: Reginster, Jean-Yves
Kaufman, Jean-Marc
Lippuner, Kurt
Langdahl, Bente
Dimai, Hans Peter
Eriksen, Erik
Claessens, Frank
Bucci-Rechtweg, Christina
Incera, Elodie
Vanderschueren, Dirk
Orwoll, Eric
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-11
Volume: 367
Issue: 18
Pages: 1714-1723
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1204061
OpenAlex: W2123816368
Cited by: 359
References: 30
Citations by year: 2026: 17 · 2025: 24 · 2024: 23 · 2023: 21 · 2022: 25 · 2021: 25 · 2020: 26 · 2019: 24 · 2018: 30 · 2017: 21 · 2016: 28 · 2015: 23 · 2014: 29 · 2013: 36 · 2012: 5
FWCI: 32.02
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Archive ouverte UNIGE (University of Geneva) (publishedVersion)
Ghent University Academic Bibliography (Ghent University) (submittedVersion)
BORIS (University Library Bern) (submittedVersion, other-oa)
IRIS (submittedVersion)
Open Repository and Bibliography (University of Liège) (submittedVersion)
University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
Open Access CRIS of the University of Bern
Funders: U.S. Department of Justice
Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Teva Pharmaceutical Industries
Danone
University of Bern
Union Chimique Belge
Daiichi-Sankyo
Novo Nordisk
Servier
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords: zoledronic acid, male osteoporosis, vertebral fractures, fracture risk reduction, bisphosphonates, androgen deficiency, bone mineral density, bone turnover markers, height loss
MeSH terms: Zoledronic Acid, Aged, Aged, 80 and over, Analysis of Variance, Diphosphonates, Double-Blind Method, Humans, Hypogonadism, Imidazoles, Male, Middle Aged, Osteoporosis, Risk, Testosterone, Bone Density, Logistic Models, Spinal Fractures, Bone Density Conservation Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks